1 In this work, the cardiovascular e ects of HPS-10, a new vasodilator agent, were studied in rats. 2 In conscious normotensive rats, oral administration of HPS-10 (4 ± 9 mg kg 71 ) produced a doserelated and long-lasting fall in systolic arterial blood pressure (ED 30 of 5.32 mg kg 71 ), accompanied by an increase in heart rate (ED 30 of 8.43 mg kg 71 ). This tachycardia was totally inhibited by pretreatment with (+)-propranolol (10 mg kg 71 , p.o.). In rat isolated rubbed aorta, HPS-10 (0.1 ± 1 mM) non-competitively and with almost equal e ectiveness antagonized the contractions induced by NA, AII (in normal Krebs solution) and Ca 2+ (in depolarizing Ca 2+ -free high-K + 50 mM solution). In the experiments in Ca 2+ -free medium, HPS-10 (1 mM) considerably inhibited the contractions induced by NA, AII and ca eine in rat aorta. 5 Furthermore, in the studies with radioactive Ca 2+ , HPS-10 (1 mM) did not modify the basal uptake of 45 Ca 2+ but strongly decreased the in¯ux of 45 Ca 2+ induced by NA, AII and K + in rat aortic rings. 6 In rat isolated atria, HPS-10 (1 mM) produced a positive inotropic/negative chronotropic e ect. 7 HPS-10 (0.3 mM) signi®cantly inhibited the sustained and transient Ba 2+ inward current (I Ba ) recorded in whole-cell clamped rat aortic myocytes. 8 These results indicate that the non-selective vasorelaxant e ects of HPS-10 in rat aortic rings can be attributed to transmembrane Ca 2+ -antagonist activity and an intracellular action on smooth muscle cells. The direct vasodilator action of HPS-10 observed in rat isolated aorta may be responsible for the HPS-10 hypotensive activity in anaesthetized normotensive rats.